Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity is a dataset published in Alzheimer s & Dementia (2022). On theSindex it has a DataRank of 1.6, placing it in the top 12.8% of the data-sharing corpus. It has been cited 61 times, with 38 citing works in its 1-hop citation network.
Ranks in the top 13% for downstream scientific impact
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.619
From this paper's citation signal
Citation Network Contribution
0.997
From 33 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 38 citers.
NIA NIH HHS
Grant: U01 AG024904
NIA NIH HHS
Grant: R56 AG061900
NIA NIH HHS
Grant: P30 AG072979
NIA NIH HHS
Grant: U19 AG024904
NIA NIH HHS
Grant: P30 AG010124
NIA NIH HHS
Grant: RF1 AG061900
Canadian Institutes of Health Research
Grant: unidentified
unidentified
National Institutes of Health
Grant: 3P30AG010124-28S1
Alzheimer's Disease Core Center - Neuroimaging Core I
National Institutes of Health
Grant: 3U19AG024904-18S3
Alzheimer's Disease Neuroimaging Initiative (ADNI4)
The Biomarkers Consortium, Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease Project was made possible through a public-private partnership managed by the Foundation for the National Institute of Health (FNIH) and funded by AbbVie Inc., Alzheimer's Association®, Diagnostics Accelerator at the Alzheimer's Drug Discovery Foundation, Biogen MA Inc., Janssen Research & Development, LLC, and Takeda Pharmaceutical Company Limited.
FWCI
7.61
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals